Navigation Links
The Lancet: New trial suggests cheaper drugs for common heart attack procedure could improve outcomes and save health budgets millions

A new study published in The Lancet compares outcomes for two drugs used to prevent blood clot formation during emergency heart attack treatment. The study suggests that use of one of the drugs, heparin, could result in improved outcomes (such as a reduced rate of repeat heart attacks), compared to the other drug tested, bivalirudin, which is in widespread use in high-income countries, and is around 400 times more expensive than heparin.

The results of the HEAT-PPCI trial suggest that systematic use of heparin rather than bivalirudin after primary percutaneous coronary intervention (PPCI) the most commonly used treatment for heart attack, which unblocks the arteries carrying blood to the heart could save health services substantial sums of money, at the same time as potentially improving patient outcomes.

Patients who undergo PPCI usually receive a combination of antithrombotic drugs to prevent any further blood clots forming during the procedure and after it has been completed. The most commonly used antithrombotic drugs are unfractionated heparin and bivalirudin, and although several previous trials have compared the two drugs, the evidence is unclear as to which drug results in better outcomes.

The trial took place at the Liverpool Heart and Chest Hospital in the UK, where 1829 patients undergoing emergency angiography (an x-ray examination of the heart's arteries after a suspected heart attack) were recruited to the trial. More than four fifths of these patients then went on to receive PPCI; approximately half received heparin, and half received bivalirudin. Researchers then recorded how many patients in both groups experienced a major adverse cardiac event, such as death or another heart attack, within 28 days after surgery.

The results show that overall rates of major adverse cardiac events were significantly lower in the group who received heparin, although the rates of adverse events were low, as expected, in both groups. Within 28 days after surgery, 46 patients (51%) in the bivalirudin group died, compared to 39 (43%) of patients in the heparin group; 24 patients (27%) in the bivalirudin group had another heart attack in the same period, compared to 7 patients (08%) in the heparin group. Although bleeding complications are an acknowledged risk of antithrombotic drugs, there was no significant difference between the groups in the rate of complications.

According to lead author Dr Rod Stables, of the Liverpool Heart and Chest Hospital NHS Foundation Trust, UK, "As far as we are aware, our study is one of the first trials to recruit 100% of eligible patients presenting with the medical condition being examined, which means that it more closely resembles real life practice than many previous trials. The results suggest that the use of heparin has some advantage over bivalirudin in avoiding major adverse events, mainly in terms of reduced recurrent, additional heart attacks in patients recovering from PPCI. This finding might provide an opportunity, rare in modern health care, to provide improved outcomes at much reduced cost."*

In a linked Comment, Peter Berger and James Blankenship of Geisinger Health System, in Pennsylvania, USA, point out that the although the study has a number of limitations including an open-label, single-centre design the study has the advantage of closely resembling actual clinical practice, and including many patients who would have been excluded from earlier trials comparing the two drugs. They write that, "Even if heparin alone had produced statistically similar outcomes to bivalirudin, it would have been a win for heparin. A drug that costs less than a 1/400th of another that has similar efficacy and safety ought to be used preferentially."

The design of the HEAT-PPCI trial has attracted some criticism within the medical community because of its use of delayed consent: patients provided their consent to participate only after they had been given either heparin or bivalirudin, leading some doctors to raise concerns that the trial design did not conform to medical ethics standards.

However, in a second linked Comment, David Shaw, of the Institute for Biomedical Ethics in Basel, Switzerland, disputes these criticisms, writing that, "In this context, the strategy was preferable to attempting to obtain consent from potentially incompetent patients needing extremely urgent cardiac treatment In routine clinical care, it would be perfectly normal for a doctor to choose either heparin or bivalirudin without involvement of the patient in the decision."

"Informed consent for percutaneous coronary intervention is frequently not sought at all; why patients should be asked to consent in advance to formal randomisation of a drug used in the intervention is thus unclear. It would have been unethical to have done the study differently. Attempting to get consent from patients would have increased the risk of harming them by delaying treatment, and could also have affected recruitment."


Contact: Matthew Back
The Lancet

Related medicine news :

1. The Lancet: Midwifery matters more than ever
2. The Lancet: UK has one of the highest death rates for children in western Europe
3. The Lancet: China halves tuberculosis prevalence in just 20 years
4. First evidence for painless atrial fibrillation treatment
5. ASPIRE Phase III trial of vaginal ring to prevent HIV completes enrollment of 2,629 women
6. GW leads clinical trial to reduce epileptic seizures in people with temporal lobe epilepsy
7. First first patient enrolled in PROSPECT II clinical trial
8. New definition of kidney disease for clinical trials could lead to new treatments
9. Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients
10. UH part of $7.5M NIH clinical trial on nearsightedness in children
11. Experimental trial represents promising step toward universal antidote for snakebite
Post Your Comments:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: